BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

US firm gets FDA nod for stem cell Ph2 trial

January 13, 2015 | News | By BioSpectrum Bureau

US firm gets FDA nod for stem cell Ph2 trial



Singapore: US based Clinical research company, Antria, has recieved FDA approval to initiate Phase 2 clinical trials with autologous adipose derived stem cells (ADSC) for plastic surgery.

"ADSCs are one of most promising avenues of medical research to use the stem cells of patients to create a more natural, longer-lasting youthful look than traditional cosmetic surgery," said Dr Leonard Maliver, chief executive officer, Antria.

"The medical benefits of Antria's research on ADSCs are not limited to cosmetic surgery. We believe we can apply our research on ADSCs to improve a wide range of medical conditions, including wound and fracture healing, congestive heart failure, and forms of arthritis."

Antria's patent-pending process uses liposuction to extract the patient's own fat.